U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H9N3O3
Molecular Weight 171.154
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METRONIDAZOLE

SMILES

CC1=NC=C(N1CCO)[N+]([O-])=O

InChI

InChIKey=VAOCPAMSLUNLGC-UHFFFAOYSA-N
InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3

HIDE SMILES / InChI

Molecular Formula C6H9N3O3
Molecular Weight 171.154
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.emedexpert.com/facts/metronidazole-facts.shtml

Metronidazole was synthesized by France's Rhone-Poulenc laboratories and introduced in the mid-1950s under the brand name Flagel in the US, while Sanofi-Aventis markets metronidazole globally under the same trade name, Flagyl, and also by various generic manufacturers. Metronidazole is one of the rare examples of a drug developed as ant parasitic, which has since gained broad use as an antibacterial agent. Metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Metronidazole is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: Trichomoniasis: symptomatic, asymptomatic, asymptomatic consorts; Amebiasis: acute intestinal amebiasis (amebic dysentery) and amebic liver abscess; Anaerobic bacterial infections; Intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess; Skin and skin structure infections; Gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection; Bacterial septicemia; Bone and joint infections, as adjunctive therapy; Central Nervous System infections, including meningitis and brain abscess; Lower Respiratory Tract infections, including pneumonia, empyema, and lung abscess; Endocarditis. Metronidazole is NOT effective for infections caused by aerobic bacteria that can survive in the presence of oxygen. Metronidazole is only effective against anaerobic bacterial infections because the presence of oxygen will inhibit the nitrogen-reduction process that is crucial to the drug's mechanism of action. Once metronidazole enters the organism by passive diffusion and activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process includes intracellular electron transport proteins such as ferredoxin, transfer of an electron to the nitro group of the metronidazole, and formation of a short-lived nitroso free radical. Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained which promotes the drug’s intracellular transport. The reduced form of metronidazole and free radicals can interact with DNA leading to inhibition of DNA synthesis and DNA degradation leading to death of the bacteria. The precise mechanism of action of metronidazole is unknown. Metronidazole has a limited spectrum of activity that encompasses various protozoans and most Gram-negative and Gram-positive anaerobic bacteria. Metronidazole has activity against protozoans like Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis, for which the drug was first approved as an effective treatment.

CNS Activity

Curator's Comment: In animal studies, metronidazole readily penetrated the blood-CSF/blood-brain barrier, and data regarding the entry into human CSF and brain abscess confirmed this finding

Originator

Curator's Comment: was synthesized by France's Rhone-Poulenc laboratories and introduced in the mid-1950s under the brand name Flagyl

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
FLAGYL

Approved Use

INDICATIONS & USAGE Metronidazole vaginal gel USP, 0.75% is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans, and Herpes simplex virus should be ruled out.

Launch Date

1963
Curative
FLAGYL

Approved Use

INDICATIONS & USAGE Metronidazole vaginal gel USP, 0.75% is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans, and Herpes simplex virus should be ruled out.

Launch Date

1963
Curative
FLAGYL

Approved Use

INDICATIONS & USAGE Metronidazole vaginal gel USP, 0.75% is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans, and Herpes simplex virus should be ruled out.

Launch Date

1963
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METRONIDAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
25 μg/mL
7.5 mg/kg 4 times / day steady-state, intravenous
dose: 7.5 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
METRONIDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
40 μg/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METRONIDAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6 μg/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METRONIDAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.77 μg/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METRONIDAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
16.54 mg/L
15 mg/kg single, intravenous
dose: 15 mg/kg
route of administration: intravenous
experiment type: single
co-administered:
METRONIDAZOLE plasma
Homo sapiens
population: unhealthy
age: ∞ants
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
75.23 μg × h/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METRONIDAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METRONIDAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8 h
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METRONIDAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METRONIDAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8 h
unknown, oral
METRONIDAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.76 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METRONIDAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
unknown, oral
METRONIDAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
12.5 g single, oral
Overdose
Dose: 12.5 g
Route: oral
Route: single
Dose: 12.5 g
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: chronic depressive illness
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hepatotoxicity...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity (9.6%)
Sources:
8.5 g single, oral
Overdose
Dose: 8.5 g
Route: oral
Route: single
Dose: 8.5 g
Sources:
unhealthy, 62 years
n = 1
Health Status: unhealthy
Condition: extensive past medical history, including end-stage renal disease
Age Group: 62 years
Sex: M
Population Size: 1
Sources:
1000 mg/m2 3 times / day steady, oral
Highest studied dose
Dose: 1000 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 1000 mg/m2, 3 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: advanced carcinoma of the colon or rectum
Age Group: adult
Sex: unknown
Population Size: 32
Sources:
DLT: Nausea and vomiting, Generalised onset motor seizure...
Dose limiting toxicities:
Nausea and vomiting (13.5%)
Generalised onset motor seizure (12.8%)
Neurotoxicity NOS (10.9%)
Sources:
5.3 mg/m2 3 times / week multiple, oral (mean)
Highest studied dose
Dose: 5.3 mg/m2, 3 times / week
Route: oral
Route: multiple
Dose: 5.3 mg/m2, 3 times / week
Co-administed with::
radiotherapy
Sources:
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: malignant brain tumors
Age Group: adult
Sex: unknown
Population Size: 28
Sources:
DLT: Gastrointestinal toxicity, Central nervous system toxicity...
Dose limiting toxicities:
Gastrointestinal toxicity (14.5%)
Central nervous system toxicity (13.7%)
Sources:
1350 mg 3 times / day steady, oral
Overdose
Dose: 1350 mg, 3 times / day
Route: oral
Route: steady
Dose: 1350 mg, 3 times / day
Sources:
unhealthy, preterm newborn
n = 1
Health Status: unhealthy
Condition: bloody stools and apnoea
Age Group: preterm newborn
Sex: F
Population Size: 1
Sources:
AEs

AEs

AESignificanceDosePopulation
Hepatotoxicity 9.6%
Disc. AE
12.5 g single, oral
Overdose
Dose: 12.5 g
Route: oral
Route: single
Dose: 12.5 g
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: chronic depressive illness
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
Neurotoxicity NOS 10.9%
DLT
1000 mg/m2 3 times / day steady, oral
Highest studied dose
Dose: 1000 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 1000 mg/m2, 3 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: advanced carcinoma of the colon or rectum
Age Group: adult
Sex: unknown
Population Size: 32
Sources:
Generalised onset motor seizure 12.8%
DLT
1000 mg/m2 3 times / day steady, oral
Highest studied dose
Dose: 1000 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 1000 mg/m2, 3 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: advanced carcinoma of the colon or rectum
Age Group: adult
Sex: unknown
Population Size: 32
Sources:
Nausea and vomiting 13.5%
DLT
1000 mg/m2 3 times / day steady, oral
Highest studied dose
Dose: 1000 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 1000 mg/m2, 3 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: advanced carcinoma of the colon or rectum
Age Group: adult
Sex: unknown
Population Size: 32
Sources:
Central nervous system toxicity 13.7%
DLT
5.3 mg/m2 3 times / week multiple, oral (mean)
Highest studied dose
Dose: 5.3 mg/m2, 3 times / week
Route: oral
Route: multiple
Dose: 5.3 mg/m2, 3 times / week
Co-administed with::
radiotherapy
Sources:
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: malignant brain tumors
Age Group: adult
Sex: unknown
Population Size: 28
Sources:
Gastrointestinal toxicity 14.5%
DLT
5.3 mg/m2 3 times / week multiple, oral (mean)
Highest studied dose
Dose: 5.3 mg/m2, 3 times / week
Route: oral
Route: multiple
Dose: 5.3 mg/m2, 3 times / week
Co-administed with::
radiotherapy
Sources:
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: malignant brain tumors
Age Group: adult
Sex: unknown
Population Size: 28
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
Endpoints of spermatotoxicity in the rat after short duration exposures to fourteen reproductive toxicants.
1992
The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model.
1992 Nov
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
[Antibiotic prophylaxys in pediatric surgery of genito-urinary abnormalities].
2002 Jun
[Antiamebic effect of metronidazole proved in a study conducted in Cienfuegos province].
2002 May-Aug
The importance of Bi-Digital O-Ring Test in the treatment of multiple hepatic abscesses: a case history.
2003
[Microbiologic characteristics of wound infectious process in use of ion-exchange sorbents].
2003
[Anaerobic bacteria in bronchoalveolar lavage fluid (BAL) after thoracic surgery].
2003
[Comparative clinical and epidemiological evaluation of beta-lactam antibiotics in the treatment of intraabdominal infections].
2003
An unexpected and severe neurological disorder with permanent disability acquired during short-course treatment with metronidazole.
2003
Superior mesenteric vein thrombosis following laparoscopic Nissen fundoplication.
2003 Apr-Jun
An open label crossover trial of effects of metronidazol on hyperlipidaemia.
2003 Aug
Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation.
2003 Aug
Renal papillary necrosis induced by naproxen.
2003 Aug
Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates.
2003 Aug 11
Metronidazole-induced encephalopathy and inferior olivary hypertrophy: lesion analysis with diffusion-weighted imaging and apparent diffusion coefficient maps.
2003 Dec
Solvent effects in permeation assessed in vivo by skin surface biopsy.
2003 Dec 18
[Vulvar amebiasis. Report of a case and review of the literature].
2003 Feb
Molecular mechanisms and biological significance of CTL avidity.
2003 Jul
A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines.
2003 May
[Evaluation on monkeys of reactogenicity and effectiveness of the complex immunoglobulin preparation formulation].
2003 May-Jun
Diazepam as a treatment for metronidazole toxicosis in dogs: a retrospective study of 21 cases.
2003 May-Jun
A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial.
2003 Nov
Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
2003 Nov 15
Ruthenium(II) sulfoxide-maltolato and -nitroimidazole complexes: synthesis and MTT assay.
2003 Nov 17
Bronchospasm and laryngeal stridor as an adverse effect of oxytocin treatment.
2003 Oct
Cardiac diphtheria in a previously immunized individual.
2003 Sep
MR imaging and diffusion-weighted imaging changes in metronidazole (Flagyl)-induced cerebellar toxicity.
2003 Sep
Crohn's disease--when to operate?
2004
[Clinical analysis of unsuccessful Helicobacter pylori eradication].
2004
[Use of arilin (Dr.Wolff) in the treatment of bacterial vaginosis and trichomoniasis during the period of 01.10.2003-31.12.2003].
2004
[Efficacy of two Helicobacter pylori eradication treatments in children with recurrent abdominal pain].
2004 Apr-Jun
Perforated appendicitis: is laparoscopy safe?
2004 Apr-Jun
TRICOM: enhanced vaccines as anticancer therapy.
2004 Aug
Nitazoxanide: a new broad spectrum antiparasitic agent.
2004 Feb
Lemierre's syndrome: the forgotten disease. An unusual presentation of sepsis.
2004 Feb
Reduced stem cell mobilization in mice receiving antibiotic modulation of the intestinal flora: involvement of endotoxins as cofactors in mobilization.
2004 Jan 1
[Tetanus in cats: 3 case descriptions].
2004 Jun
A case of clarithromycin-induced manic episode (antibiomania).
2004 Mar
Reproductive and cytogenetic toxicity of metronidazole in male mice.
2004 May
Experience with routine intraabdominal cultures during laparoscopic gastric bypass with implications for antibiotic prophylaxis.
2004 May
Reversible cerebellar lesions induced by metronidazole therapy for helicobacter pylori.
2004 Oct
Thoracic spondylitis from a mycotic (Streptococcus pneumoniae) aortic aneurysm: a case report.
2004 Sep 1
Metronidazole-induced encephalopathy.
2004 Sep 15
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
2005 Feb 1
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
2005 Feb 15
Is operative management effective in treatment of perforated typhoid?
2005 Mar
[Two cases of metronidazole-induced encephalopathy].
2005 Mar
Abnormal enhancing lesion of dentate nuclei causing neurologic symptoms induced by metronidazole toxicity.
2005 Mar
Can antibiotics prevent preterm birth--the pro and con debate.
2005 Mar
Patents

Sample Use Guides

Trichomoniasis: In the Female: One-day treatment − two grams of FLAGYL, given ither as a single dose or in two divided doses of one gram each, given in the same day. Anaerobic Bacterial Infections: In the treatment of most serious anaerobic infections, intravenous metronidazole is usually administered initially. The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period. Amebiasis: Adults: For acute intestinal amebiasis (acute amebic dysentery): 750 mg orally three times daily for 5 to 10 days. For amebic liver abscess: 500 mg or 750 mg orally three times daily for 5 to 10 days. Pediatric patients: 35 to 50 mg/kg/24 hours, divided into three doses, orally for 10 days.
Route of Administration: Other
Cells incubated with lethal drug (Metronidazole (MTZ)) concentration exhibit unchanged DNA profile, only about 50% of cells are positive for γH2A and lose an ability to attach to a surface after few hours of incubation. It is likely that the early reaction of cells to lethal concentration of MTZ is not primarily initiated by the reaction to DNA damage but rather by the immediate interaction of MTZ with biomolecules where activated MTZ is generated.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:11:19 GMT 2023
Edited
by admin
on Fri Dec 15 15:11:19 GMT 2023
Record UNII
140QMO216E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METRONIDAZOLE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
METRONIDAZOLE COMPONENT OF HELIDAC
Common Name English
METRONIDAZOLE [WHO-IP]
Common Name English
VANDAZOLE
Brand Name English
METRONIDAZOLE BENZOATE IMPURITY A [EP IMPURITY]
Common Name English
METROMIDOL
Brand Name English
FLAGYL
Brand Name English
NSC-50364
Code English
METRONIDAZOLE COMPONENT OF PYLERA
Common Name English
BAYER 5360
Code English
METRONIDAZOLE [IARC]
Common Name English
Metronidazole [WHO-DD]
Common Name English
METRONIDAZOLE [USAN]
Common Name English
PYLERA COMPONENT METRONIDAZOLE
Common Name English
METROGEL
Brand Name English
METRONIDAZOLE [USP IMPURITY]
Common Name English
METRONIDAZOLE [MI]
Common Name English
DEFLAMON
Common Name English
METRONIDAZOLE [HSDB]
Common Name English
METRONIDAZOLE [EP MONOGRAPH]
Common Name English
SATRIC
Brand Name English
2-Methyl-5-nitroimidazole-1-ethanol
Systematic Name English
HELIDAC COMPONENT METRONIDAZOLE
Common Name English
metronidazole [INN]
Common Name English
RP 8823
Code English
METRONIDAZOLE [VANDF]
Common Name English
RP-8823
Code English
METRONIDAZOLE [USP-RS]
Common Name English
METRO I.V.
Brand Name English
BAYER-5360
Code English
PROTOSTAT
Brand Name English
METRONIDAZOLE [ORANGE BOOK]
Common Name English
METRONIDAZOLE [JAN]
Common Name English
ORVAGIL
Common Name English
METRONIDAZOLE [EP IMPURITY]
Common Name English
NORITATE
Brand Name English
METROLOTION
Brand Name English
METROCREAM
Brand Name English
METROGEL-VAGINAL
Brand Name English
GINEFLAVIR
Common Name English
METRONIDAZOLE [USP MONOGRAPH]
Common Name English
ZADSTAT
Common Name English
METRONIDAZOLE [MART.]
Common Name English
NSC-69587
Code English
LIKMEZ
Brand Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 6.5.1
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-VATC QA02BD02
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
NDF-RT N0000175435
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.2
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC P01AB01
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-VATC QG01AF01
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC J01XD01
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC A02BD01
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC J01RA10
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC G01AF01
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC A02BD03
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC D06BX01
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC A02BD11
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC J01RA04
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
LIVERTOX NBK548609
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
CFR 21 CFR 530.41
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
FDA ORPHAN DRUG 17486
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-VATC QP51AA01
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-VATC QA02BD03
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
NCI_THESAURUS C279
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
EU-Orphan Drug EU/3/11/875
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
FDA ORPHAN DRUG 267008
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
EPA PESTICIDE CODE 120401
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC P01AB51
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC A02BD02
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
FDA ORPHAN DRUG 339111
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC J01RA03
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC A02BD08
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-VATC QD06BX01
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
FDA ORPHAN DRUG 247907
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
FDA ORPHAN DRUG 21687
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-VATC QJ01XD01
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
FDA ORPHAN DRUG 514715
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
NDF-RT N0000007663
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-VATC QA01AB17
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
FDA ORPHAN DRUG 61891
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-VATC QA02BD08
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
NDF-RT N0000007663
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-VATC QA02BD01
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
WHO-ATC A01AB17
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
Code System Code Type Description
SMS_ID
100000090285
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
ECHA (EC/EINECS)
207-136-1
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
PUBCHEM
4173
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
INN
1032
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
CAS
443-48-1
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
NCI_THESAURUS
C651
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID2020892
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
NSC
69587
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
LACTMED
Metronidazole
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
RS_ITEM_NUM
1442009
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
CHEBI
6909
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
MESH
D008795
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
METRONIDAZOLE
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY Description: A white or pale yellow, crystalline powder; odourless or almost odourless.Solubility: Sparingly soluble in water; slightly soluble in ethanol (~750 g/l) TS and ether R.Category: Antitrichomonal; antiamoebic. Storage: Metronidazole should be kept in a well-closed container, protected from light. Additional information: Metronidazole is stable in air, but darkens on exposure to light. Definition: Metronidazole contains not less than 99.0% and not more than 101.0% of C6H9N3O3, calculated with reference to the dried substance.
CHEBI
50687
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
DRUG CENTRAL
1790
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
EVMPD
SUB08922MIG
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
ChEMBL
CHEMBL137
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
RXCUI
6922
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY RxNorm
NSC
50364
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
FDA UNII
140QMO216E
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
HSDB
3129
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
DAILYMED
140QMO216E
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
MERCK INDEX
m7506
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
METRONIDAZOLE
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
DRUG BANK
DB00916
Created by admin on Fri Dec 15 15:11:19 GMT 2023 , Edited by admin on Fri Dec 15 15:11:19 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INHIBITOR
POTENT
BINDER->LIGAND
BINDING
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC POPULATION: CHILDREN AND ADOLESCENTS

MIC BIOLOGICAL PATHOGEN: ANAEROBES

SUSCEPTIBILITY: INTERMEDIATE

Tmax PHARMACOKINETIC FORMULATION: IMMEDIATE RELEASE

MIC BIOLOGICAL PATHOGEN: ANAEROBES

SUSCEPTIBILITY: RESISTANT

Biological Half-life PHARMACOKINETIC POPULATION: ADULTS

Biological Half-life PHARMACOKINETIC POPULATION: NEONATES 7 DAYS AND OLDER

Biological Half-life PHARMACOKINETIC CHILD-PUGH CLASSIFICATION: CLASS A

MIC BIOLOGICAL PATHOGEN: ANAEROBES

SUSCEPTIBILITY: SUSCEPTIBLE

Biological Half-life PHARMACOKINETIC POPULATION: NEONATES GESTATIONAL AGE 36-40 WEEKS

Biological Half-life PHARMACOKINETIC POPULATION: NEONATES GESTATIONAL AGE 32-35 WEEKS

Biological Half-life PHARMACOKINETIC CREATININE CLEARANCE: LESS THAN OR EQUAL TO 65 ML/MIN

RENAL FUNCTION: IMPAIRED

Tmax PHARMACOKINETIC FORMULATION: EXTENDED RELEASE

Biological Half-life PHARMACOKINETIC CHILD-PUGH CLASSIFICATION: CLASS C

Biological Half-life PHARMACOKINETIC CHILD-PUGH CLASSIFICATION: CLASS B

Biological Half-life PHARMACOKINETIC POPULATION: NEONATES GESTATIONAL AGE 28-30 WEEKS